Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Mindera Health

Shaping the Era of Digital Predictive Skin Analytics

## Sitemaps

- [XML Sitemap](https://minderahealth.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Mindera Health™ Awarded New York State Department of Health Approval for Mind.Px™](https://minderahealth.com/mindera-health-awarded-new-york-state-department-of-health-approval-for-mind-px/) - Decision brings precision medicine in psoriasis to all 50 states Vista, CA, April 22, 2026 (GLOBE NEWSWIRE) — Mindera Health, a leader in precision medicine for dermatological conditions, today announced it has received approval from the New York State Department of Health for its Mind.Px test. Mind.Px is a genomic test that utilizes the proprietary
- [Mindera Health™ and Mountaineer Biosciences Launch Subtilitas, a Precision Translational Medicine Platform for Dermatology and Immunology](https://minderahealth.com/mindera-health-and-mountaineer-biosciences-launch-subtilitas-a-precision-translational-medicine-platform-for-dermatology-and-immunology/) - Vista, CA, March 18, 2026 (GLOBE NEWSWIRE) — Mindera Health, a leader in precision medicine for dermatological conditions, and Mountaineer Biosciences today announced the launch of Subtilitas, a precision translational medicine platform designed to bring objective, molecular-level insights into dermatology and immunology clinical researchSubtilitas integrates non-invasive skin sampling, advanced molecular profiling, and artificial intelligence/machine learning
- [Mindera Health™ announces publication of randomized, prospective clinical utility study demonstrating improved psoriasis patient outcomes](https://minderahealth.com/mindera-health-announces-publication-of-randomized-prospectiveclinical-utility-study-demonstrating-improved-psoriasis-patient-outcomes/) - Using Mind.Px™ test results, altered physician prescribing behavior leads to faster,more effective patient outcomes Vista, CA, May 13, 2025 (GLOBE NEWSWIRE) Mindera Health, a leader in precision medicine for dermatological conditions, today announced positive results from the completion of a randomized, prospective clinical trial (MATCH) aimed at demonstrating the clinical utility of Mind.Px™, the first
- [Mindera Health™ Signs Network Provider Agreement with MultiPlan](https://minderahealth.com/mindera-health-signs-network-provider-agreement-with-multiplan/) - Mindera Health, a leader in precision medicine for dermatological conditions, today announced their participation in MultiPlan’s national PPO networks. Effective immediately, health plan members who access MultiPlan’s PHCS and MultiPlan Networks have access to Mindera’s Vista, CA-based laboratory that performs its proprietary test Mind.Px™.“Our vision is to realize the clinical and economic benefits of precision
- [Mindera Health™ Welcomes New Vice President of Sales](https://minderahealth.com/mindera-health-welcomes-new-vice-president-of-sales/) - – Mindera Health, a pioneer in precision medicine combining machine learning with Next-Generation Sequencing to create Dermal Intelligence™, announces the addition of John Wegener as the New VP of Sales.John has deep experience and impressive accomplishments across his career, including most recently 10 years as Senior Vice President Sales and Marketing at Exagen Inc. and
- [Mindera Health™ Announces Issuance of Additional International Patent Coverage for Dermal Biomarker Patch Platform](https://minderahealth.com/mindera-health-announces-issuance-of-additional-international-patent-coverage-for-dermal-biomarker-patch-platform-2/) - Mindera Health, a precision medicine company developing personalized tools to optimize patient outcomes, today announced that additional patent protection has been issued in Japan for the core technology behind the dermal biomarker patch. Japanese patent number JP7572774 was issued October 16, 2024 and describes devices that can extract dermal biomarkers in situ. The inventors discovered
- [Mindera Health Partners with National Psoriasis Foundation to Advance Precision Medicine in Psoriasis Treatment](https://minderahealth.com/mindera-health-partners-with-national-psoriasis-foundation-to-advance-precision-medicine-in-psoriasis-treatment/) - Mindera Health and National Psoriasis Foundation partner to improve psoriasis patient outcomes and raise awareness of precision medicine. Vista, CA- November 19, 2024- Mindera Health, a leader in precision medicine for dermatological conditions, today announced a strategic partnership with the National Psoriasis Foundation (NPF), the largest patient advocacy organization dedicated to serving those with
- [Mindera Health™ becomes a Medi-Cal™ Credentialled Provider](https://minderahealth.com/mindera-health-becomes-a-medi-cal-credentialled-provider/) - Provider status with Medi-Cal will allow Mindera Health to provide its proprietary Mind.Px test to predict biologic class response in plaque psoriasis to the over 15 million Medi-Cal Beneficiaries. San Diego, CA, Aug 19, 2024 (GLOBE NEWSWIRE) -- Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has completed the credentialling
- [Mindera Health Announces Appointment of Kamal Adawi as Chief Financial Officer](https://minderahealth.com/mindera-health-announces-appointment-of-kamal-adawi-as-chief-financial-officer/) - Mindera Health announces the appointment of Kamal Adawi as Chief Financial Officer, effective August 14th, 2024. San Diego, CA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Ron Rocca, President and CEO of Mindera Health, said, “We’re very pleased to add Kamal to the executive team. I am thrilled to work with Kamal again as he will
- [Mindera Health Secures $14 Million to Advance Commercialization of First and Only Psoriasis Precision Medicine Test](https://minderahealth.com/mindera-health-secures-14-million-to-advance-commercialization-of-first-and-only-psoriasis-precision-medicine-test/) - San Diego, CA, July 31, 2024 (GLOBE NEWSWIRE) -- Mindera Health Inc. announces the closing of a $14M convertible note financing, led by Mountain Group Partners and other existing investors in anticipation of a Series B financing in 2025. Proceeds will support the continued commercialization of Mindera’s lead product, Mind.Px™. “This capital raise will fuel
- [THE LOCALIST SD Precision Medicine disrupts the medical world](https://minderahealth.com/the-localist-sd-precision-medicine-disrupts-the-medical-world/) - Mindera Health is disrupting the world of medicine. Ashley takes you inside their Carlsbad headquarters to see how this new psoriasis predictive test is changing lives for the better. Mindera Health founder Toby Dickerson explains it all. See More: Precision Medicine disrupts the medical world | FOX 5 San Diego & KUSI News
- [Mindera Health™ Launches Program with Innovative Pharmacy Benefit Manager to Improve Management of Moderate-to-Severe Psoriasis Patients Through Precision Medicine](https://minderahealth.com/mindera-health-launches-program-with-innovative-pharmacy-benefit-manager-to-improve-management-of-moderate-to-severe-psoriasis-patients-through-precision-medicine/) - Innovative collaboration will improve patient outcomes and cost savings through reduced trial-and-error management of biologic therapiesMindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has formed a partnership with Liviniti™, an innovative Pharmacy Benefit Manager, to improve the management of moderate-to-severe psoriasis patients. This pilot program will utilize Mind.Px to improve
- [Mindera Health ™ Announces Commercial Relocation](https://minderahealth.com/mindera-health-announces-relocation/) - San Diego, CA – November 27th, 2023 – Mindera Health™, a leading provider of precision medicine solutions for psoriasis, today announced that it will be relocating its commercial activities to a new office building at 1221 Liberty Way, Vista, CA 92081 on December 1st, 2023. The new facility is over 19,000 square feet and features
- [Mindera Health ™ announces the signing of a commercial agreement with Occum Health for Mind.Px ™](https://minderahealth.com/mindera-health-announces-the-signing-of-a-commercial-agreement-with-occum-health-for-mind-px/) - San Diego, CA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Mindera Health today announces the signing a commercial agreement with Occum Health, LLC, a healthcare solutions company that is focused on delivering savings and improved benefits to self-insured employers. Through this agreement, Mindera’s proprietary psoriasis biologic prediction test, Mind.Px, is available to Occum Health’s more than
- [Mindera Inc. Signs Provider Contract with Provider Network Contigo Health ConfigureNet(™)](https://minderahealth.com/mindera-inc-signs-provider-contract-with-provider-network-contigo-health-configurenet/) - San Diego, CA, Oct 23, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, announces that it has signed a provider contract with Contigo Health ConfigureNetTM provider network. This commercial agreement will make Mindera's psoriasis biologic prediction test, Mind.Px, available to clients and their health plan members
- [Mindera Health™ Announces Issuance of Additional International Patent Coverage for Dermal Biomarker Patch Platform](https://minderahealth.com/mindera-health-announces-issuance-of-additional-international-patent-coverage-for-dermal-biomarker-patch-platform/) - Mindera Health, a precision medicine company developing personalized tools to optimize patient outcomes, today announced that additional patent protection has been issued in Australia for the core technology behind the dermal biomarker patch. Australian patent number 2020239750 was issued August 3, 2023 and covers devices that can extract dermal biomarkers in situ. The inventors
- [Mindera Health™ Announces Contract With General Services Administration®](https://minderahealth.com/mindera-health-announces-contract-with-general-services-administration/) - Mindera Corp dba Mindera Health today announced that the General Services Administration (GSA) has awarded a 5-year contract to Mindera Health, enabling access to the Mind.Px™ test for patients with plaque psoriasis considering biologic therapy. San Diego, CA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Mindera Health today announced that the General Services Administration (GSA) has
- [Mindera Health™ Signs Contract with Nationwide Provider Network MediNcrease™](https://minderahealth.com/mindera-health-signs-contract-with-nationwide-provider-network-medincrease/) - San Diego, CA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Mindera Health™ today announces the signing of a network provider contract with MediNcrease Health Plans, a national provider network and provider advocacy firm. This commercial agreement will make Mindera’s psoriasis biologic prediction test, Mind.Px™, available to the more than 15 million lives served by Clients and
- [Samuel “Bo” Bartholomew](https://minderahealth.com/samuel-bo-bartholomew/) - Samuel “Bo” Bartholomew is CEO of EvidenceCare and Managing Partner of Rockmont Investments. Bo leads EvidenceCare’s effort to empower better care decisions within the EHR so that every clinical decision will provide the right care at the right time. He also serves on the board of ProviderTrust and Mindera Health with the goal of bringing
- [Mindera Health™ Announces Change to Executive Leadership Team](https://minderahealth.com/mindera-health-announces-change-to-executive-leadership-team/) - Ron Rocca to Become Chief Executive Officer SAN DIEGO, CA – May 11, 2023 – Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive leadership team. The company has announced industry veteran Ron Rocca will succeed George Mahaffey as President and Chief Executive
- [Mark Lebwohl](https://minderahealth.com/mark-lebwohl/) - Dr. Mark Lebwohl graduated summa cum laude from Columbia College in 1974 and graduated from Harvard Medical School in 1978. He completed residencies in internal medicine and dermatology, both at Mount Sinai. Dr. Lebwohl has been practicing dermatology since 1983. He is the Waldman Professor and Chair of the Kimberly and Eric J. Waldman Department
- [Mindera Health™ Announces Coverage with Evidence Project with Highmark, Inc. to Advance Moderate-to-Severe Psoriasis Patient Care and Reduce Specialty Drug Spending](https://minderahealth.com/mindera-health-announces-coverage-with-evidence-project-with-highmark-inc-to-advance-moderate-to-severe-psoriasis-patient-care-and-reduce-specialty-drug-spending/) - Mindera Health™ Announces Coverage with Evidence Project with Highmark, Inc. to Advance Moderate-to-Severe Psoriasis Patient Care and Reduce Specialty Drug Spending Project will evaluate Mind.Px’s™ impact on physician “trial and error” prescribing behavior and overall net savings by prescribing the correct biologic class the first time SAN DIEGO, CA – April 11, 2023 – Mindera
- [Mindera Health™ Appoints Linh H. Le as Chief Financial Officer and Chief Operating Officer](https://minderahealth.com/mindera-health-appoints-linh-h-le-as-chief-financial-officer-and-chief-operating-officer/) - Mindera Health™ Appoints Linh H. Le as Chief Financial Officer and Chief Operating Officer Industry Veteran will assist in commercialization of Mind.PxTM to implement precision medicine for biologic treatment of moderate-to-severe psoriasis SAN DIEGO, CA – March 14, 2023 – Mindera Health, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has
- [Mindera Health™ Closes Upsized $20M Series A-3 Financing](https://minderahealth.com/mindera-health-closes-upsized-20m-series-a-3-financing/) - [SAN DIEGO, CA – December 12, 2022] Mindera Health has completed a $20.3 million Series A-3 financing, led by Mountain Group Partners, Rockmont Investments, and Scientific Health Development, to continue its aggressive growth strategy for the company’s groundbreaking precision medicine technology in the dermatology space. The funds will be used to expand the commercialization of Mind.Px™,
- [Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients](https://minderahealth.com/interim-results-of-match-study-demonstrate-improved-decision-making-and-clinical-outcomes-when-using-mind-px-to-determine-biologic-drug-class-for-psoriasis-patients/) - By Using Mind.Px, Patients Achieve PASI75 Faster than Treatment-as-Usual Cohort SAN DIEGO, CA – October 20, 2022 – Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px™ test from the ongoing MATCH study were recently presented at the Fall Clinical Dermatology Conference 2022 in Las Vegas, one of the largest US-based dermatology educational
- [Mindera Health™ announces publication of a consensus panel opinion that positive results from the MATCH Study would prove clinical utility for precision medicine test Mind.Px™](https://minderahealth.com/mindera-health-announces-publication-of-a-consensus-panel-opinion-that-positive-results-from-the-match-study-would-prove-clinical-utility-for-precision-medicine-test-mind-px/) - Mind.Px provides clinically actionable information to physicians prior to treatment choice that significantly reduces “trial and error” biologic drug prescribing behavior, leading to improved psoriasis patient outcomes and reductions in wasted spending SAN DIEGO, CA – July 26, 2022 – Mindera Health announces the publication, in the Journal of Drugs in Dermatology, of the
- [Mindera Health™ Launches Pilot with National Health Insurance Company to Improve Management of Moderate-To-Severe Psoriasis Patients Through Precision Medicine](https://minderahealth.com/mindera-health-launches-pilot-with-national-health-insurance-company-to-improve-management-of-moderate-to-severe-psoriasis-patients-through-precision-medicine/) - Pilot designed to use clinical utility and patient outcomes to validate cost savings and address wasted spend and net savings from “trial and error” medicine SAN DIEGO, CA – April 28, 2022 – Mindera Health™, the developer of the groundbreaking Dermal Intelligence™ platform - the first realization of precision medicine in psoriasis, has initiated
- [April W. Armstrong, MD, MPH](https://minderahealth.com/april-w-armstrong-md-mph/)
- [Tobin Dickerson, PhD](https://minderahealth.com/tobin-dickerson-ph-d/) - Tobin Dickerson joined MiNDERA from the The Scripps Research Institute where he was an Associate Professor in the Department of Chemistry and the Worm Institute for Research and Medicine from 2005-2019. He completed his BS with high honors in Chemistry from the University of Virginia in 1999, and subsequently was awarded his MA in Chemistry
- [Mindera Health™ Appoints Deborah L. Rice-Johnson to its Board of Directors](https://minderahealth.com/mindera-health-appoints-deborah-l-rice-johnson-to-its-board-of-directors/) - SAN DIEGO, CA – March 1, 2022 – Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis, has appointed Deborah L. Rice-Johnson to its Board of Directors, effective February 28, 2022. Ms. Rice-Johnson has more than 30 years of experience in the health insurance industry.
- [Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients](https://minderahealth.com/mindera-health-and-welldyne-announce-a-definitive-agreement-to-improve-management-of-moderate-to-severe-psoriasis-patients/) - Partnership to focus on improving patient outcomes while reducing healthcare system costs of expensive biologic therapeutics SAN DIEGO, CA and LAKELAND, FL – January 4, 2022 – Mindera Health™ and WellDyne have entered into a definitive agreement to improve the management of psoriasis patients with moderate to severe disease using a proprietary dermal biomarker patch
- [Mindera Health™ announces first patient enrolled in the MATCH Study; a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics](https://minderahealth.com/mindera-health-announces-first-patient-enrolled-in-the-match-study-a-clinical-utility-evaluation-of-the-impact-of-mind-px-on-response-rates-of-psoriasis-patients-who-are-prescribed/) - Mind.Px brings personalized medicine to psoriasis patients by improving pre-treatment biologic drug class choice with >90% positive predictive value SAN DIEGO – October 21, 2021 – Mindera Health, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis, announced the enrollment of the first patient in the MATCH
- [Mindera Health™ announces publication of positive results from STAMP-1 and STAMP-2 studies](https://minderahealth.com/mindera-health-announces-publication-of-positive-results-from-stamp-1-and-stamp-2-studies/) - Observational studies leverage machine learning to create Mind.PxTM, a test that prospectively predicts biologic class response for individual psoriasis patients with high Positive Predictive Values (PPV) SAN DIEGO, CA – November 16, 2021 – Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis, has announced
- [Mindera Corporation Shifts Name to Mindera Health to Sharpen Focus on Its Personalized Medicine Platform](https://minderahealth.com/mindera-corporation-shifts-name-to-mindera-health-to-sharpen-focus-on-its-personalized-medicine-platform/) - Combining Machine Learning with Next-Generation Sequencing creates Dermal Intelligence™: actionable information for payers, providers and patients to improve health outcomes and reduce healthcare spending. (SAN DIEGO, CA – October 5, 2021) Mindera Corporation, developers of the groundbreaking Mind.Px™ - the first realization of truly personalized medicine in psoriasis - has changed its name to Mindera
- [Mindera Corporation Raises $5.3M Series A to Commercialize Psoriasis Biologic Responsiveness Test](https://minderahealth.com/mindera-corporation-raises-5-3m-series-a-to-commercialize-psoriasis-biologic-responsiveness-test/) - SAN DIEGO, CA - Mindera Corporation has announced that it closed a $5.3M Series A financing on November 14, 2019 led by Mountain Group Partners and Scientific Health Development. The funding will be used to commercialize Mind.Px, a groundbreaking tool to prospectively predict patient response to expensive psoriasis biologics, as well as to continue development
- [Mindera Corporation Announces Appointment of George W. Mahaffey as President and Chief Executive Officer](https://minderahealth.com/mindera-corporation-announces-appointment-of-george-w-mahaffey-as-president-and-chief-executive-officer/) - SAN DIEGO, July 27, 2020 /PRNewswire/ -- Mindera Corporation has announced that George W. Mahaffey was appointed President and Chief Executive Officer, and will also serve as a Director of the Company. Treatment of chronic skin conditions is a major cost burden to the health care system. In particular, moderate to severe psoriasis patients often require very expensive biologic drug
- [Mindera Announces CLIA Certification Achieved by its Diagnostics Laboratory](https://minderahealth.com/mindera-announces-clia-certification-achieved-by-its-diagnostics-laboratory/) - SAN DIEGO, CA - Mindera Corporation has announced that its San Diego diagnostics laboratory has successfully passed the State of California survey for Clinical Laboratory Improvement Amendments (CLIA) certification. Under this certification, Mindera now has permission to begin offering molecular diagnostic services to patients. Mindera has a developed a novel platform to extract thousands of
- [Mindera to Present Precision Medicine Test for Psoriasis Biologics at Dermatology Summit 2021](https://minderahealth.com/mindera-to-present-precision-medicine-test-for-psoriasis-biologics-at-dermatology-summit-2021-2/) - SAN DIEGO, CA - Mindera Corporation announced that it has been invited to present Mind.Px, their flagship Precision Medicine test for predicting patient response to psoriasis biologics, at the 8th Annual Dermatology Summit. The Dermatology Summit is the premier national commercial dermatology conference and is timed to coincide annually with the J.P. Morgan Healthcare Conference.
- [Mindera Selected as Finalist in Terra2 Solutions Skin Health Innovation Competition at Winter Clinical Dermatology Conference](https://minderahealth.com/mindera-selected-as-finalist-in-terra2-solutions-skin-health-innovation-competition-at-winter-clinical-dermatology-conference/) - SAN DIEGO, CA - Mindera Corporation announced that it has been selected as a finalist in the Terra2 Solutions Skin Heath Innovation Conference at the Winter Clinical Dermatology Conference. Mindera will be presenting Mind.Px, its flagship Precision Medicine test for predicting patient response to psoriasis biologics. The competition highlights companies that have developed new technologies
- [Mindera wins Prestigious Terra2 Skin Health Innovations Competition at 2021 Winter Clinical Dermatology Conference](https://minderahealth.com/mindera-wins-prestigious-terra2-skin-health-innovations-competition-at-2021-winter-clinical-dermatology-conference/) - SAN DIEGO, CA - Mindera Corporation announced that it has won the prestigious Terra2 Skin Health Innovations Competition at the 2021 Winter Clinical Dermatology Conference. The Winter Clinical Dermatology Conference is an annual conference for dermatologists and dermatology residents to further education and discuss breakthrough innovations in their specialty. Tobin Dickerson, Ph.D., Chief Scientific Officer
- [Mindera™ Honored as Winner in 2021 MedTech Breakthrough Awards Program, Best New Technology Solution – Dermatology](https://minderahealth.com/mindera-honored-as-winner-in-2021-medtech-breakthrough-awards-program-best-new-technology-solution-dermatology/) - Mindera dermal biomarker patch technology generates clinically validated data to lower healthcare costs and improve patient outcomes SAN DIEGO – May 6, 2021 – Mindera Corporation today announced that it has been selected as the winner of the “Best New Technology Solution for Dermatology” award in the fifth annual MedTech Breakthrough Awards program conducted by
- [Mindera Raises Over $12M Series A-2 Financing](https://minderahealth.com/mindera-raises-over-12m-series-a-2-financing/) - SAN DIEGO – May 11, 2021 – Mindera Corporation today announced a $12.6M Series A-2 capital raise. The round was led by Mountain Group Partners, Rockmont Investments, and Scientific Health Development. The funding will be used to commercialize Mind.Px, a groundbreaking tool to prospectively predict patient response to expensive psoriasis biologics, as well as continue
- [Mindera ™ announces publication of an economic evaluation of precision medicine testing for the treatment of psoriasis](https://minderahealth.com/mindera-announces-publication-of-an-economic-evaluation-of-precision-medicine-testing-for-the-treatment-of-psoriasis/) - Model yielded average cost savings per patient of $8,492 annually as well as an average annual wasted spend savings of $16,567 SAN DIEGO – July 19, 2021 – Mindera Corporation today announced that SKIN: The Journal of Cutaneous Medicine has published “An economic evaluation of the budget impact of precision medicine testing for the treatment
- [Mindera Survey Confirms the Impact of Physician Trial-and-Error Behavior on Psoriasis Biologic Treatment](https://minderahealth.com/mindera-survey-confirms-the-impact-of-physician-trial-and-error-behavior-on-psoriasis-biologic-treatment/) - Study shows 98% of dermatologists would utilize Mind.Px to predict biologic response for psoriasis patients SAN DIEGO – July 26, 2021 – Mindera Corporation today announced that Dermatology and Therapy published results from a survey of 43 community-based dermatologists on behaviors and preferences of psoriasis-treating physicians. The survey revealed a widespread and costly trial-and-error cycle
- [Dermatology Industry Veteran Ann Deren-Lewis Joins Mindera as Chief Commercial Officer](https://minderahealth.com/dermatology-industry-veteran-ann-deren-lewis-joins-mindera-as-chief-commercial-officer/) - Deren-Lewis will lead the company’s aggressive commercialization plans for the first personalized medicine platform specific to the dermatology industry. (SAN DIEGO, CA – August 2, 2021) Mindera Corporation, developers of the groundbreaking Dermal Intelligence™ platform - the first realization of personalized medicine in dermatology - has appointed renowned industry veteran Ann Deren-Lewis as its Chief Commercial
- [Tahir Mahmood, PhD](https://minderahealth.com/tahir-mahmood/) - Tahir Mahmood is co-founder of Mindera Health and co-invented and developed the company’s core technology platform. He is Chief Executive Officer and Co-founder at Applied Molecular Transport (NASDAQ: AMTI), a clinical stage biotech developing oral targeted biological therapeutics for treating immune-mediated inflammation, metabolic and other diseases. Previously, Tahir was a leader in the US West Coast
- [Andrew Offer](https://minderahealth.com/andrew-offer/) - Andrew Offer has been a member of the MiNDERA Board of Directors since 2015. He is a General Partner and the Chief Executive Officer of Scientific Health Development. With over 15 years of healthcare investment experience, Mr. Offer serves on the board of directors for most active SHD portfolio companies including Sight Sciences (Nasdaq: SGHT),
- [Craig L. Leonardi, MD](https://minderahealth.com/craig-leonardi/) - Dr. Leonardi is Adjunct Professor of Dermatology at St. Louis University Medical School in St. Louis, Missouri, where he also has a private practice. He received his medical degree from the University of Miami School Of Medicine in Florida and completed an internship in pediatrics and residency in dermatology at the University of Miami/Jackson Memorial
- [Joseph Cook, III](https://minderahealth.com/joseph-cook-iii/) - Joseph Cook III has served as a member of our board of directors since August 2019. Since February 2003, Mr. Cook has served as a Managing Director at Mountain Group Partners, an investment firm with investments in the Life Sciences, AgTech and Technology sectors. From January 2001 until February 2003, Mr. Cook served as a
- [Dr. Alan Menter, MD - Chairman](https://minderahealth.com/dr-alan-menter/) - Dr. Alan Menter was born in England and is a graduate of the Medical School of the University of Witwatersrand, South Africa. He completed his dermatology residency at Pretoria General Hospital at the University of Pretoria, also in South Africa, and two fellowships in London at Guy's Hospital and St. John's Hospital for Diseases of
- [Bruce E. Strober, MD, PhD](https://minderahealth.com/bruce-e-strober-md-phd/) - Clinical Professor, Department of Dermatology Yale University, New Haven, CT USA and Central Connecticut Dermatology Research, Cromwell, CT USA Co-Scientific Director of the Corrona Psoriasis RegistrySecretary-Treasurer of the International Psoriasis CouncilEditor in Chief of the Journal of Psoriasis and Psoriatic Arthritis Dr. Strober earned both his medical degree and his doctorate from Columbia University College
- [David M. Pariser, MD, FACP, FAAD](https://minderahealth.com/david-m-pariser-md-facp-faad/) - Dr. Pariser is a Professor in the Department of Dermatology at Eastern Virginia Medical School in Norfolk, Virginia, where he is also the senior physician at Pariser Dermatology Specialists, Ltd., a private group practice of 17 dermatologists, 6 PAs and nurse practitioners, with multiple locations in Southeastern Virginia and is the President and Principal Investigator

## Pages

- [Home](https://minderahealth.com/) - In only five minutes and a penny-sized patch, Mindera Health technology captures thousands of RNA transcripts. We enable scalable collection and analysis of individualized genetic information to provide actionable, data-driven decisions for patients, providers and payers.
- [Team](https://minderahealth.com/team-mindera-health/) - Shaping The Era of Digital Predicative Skin Analytics The Team Meet Our People Mindera Health has assembled an Executive Team with a proven track record of both improving health economic outcomes and commercializing technology through IPOs, M&A, and transformative distribution agreements. The company is guided by a seasoned Board of Directors that includes Venture Capital
- [TAHIR MAHMOOD, PHD](https://minderahealth.com/tahir-mahmood-phd/) - About Tahir Mahmood was co-founder of Mindera Health and co-invented and developed the company’s core technology platform. He is Chief Executive Officer and Co-founder at Applied Molecular Transport (NASDAQ: AMTI), a clinical stage biotech developing oral targeted biological therapeutics for treating immune-mediated inflammation, metabolic and other diseases. Previously, Tahir was a leader in the US
- [Precision Medicine Podcasts](https://minderahealth.com/precision-medicine-podcasts/) - Precision Medicine Podcasts
- [Contact Us](https://minderahealth.com/contact-us/) - Connect with Mindera Health: Get in touch today and learn how our Mind.Px can help Psoriasis Patients.
- [Physician Resources](https://minderahealth.com/physician-resources/) - Physician Resources Precision Medicine Realized... Mind.Px™ is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value. Mind.Px™ Test Resources Test Requisition Form (TRF) Specimen
- [Order Test](https://minderahealth.com/order-test/) - Order a Mind.Px test to confidently prescribe the right biologic drug class for your psoriasis patient.
- [Patient Resources](https://minderahealth.com/patient-resources/) - Mind.Px Patients had better outcomes with Mind.Px One study showed when a patient’s biologic treatment choice was informed by the Mind.Px test results, disease improvement was achieved faster versus patients whose physicians did not receive the Mind.Px test results. Billing We offer tailored payment plans to accommodate certain financial circumstances. For more information, please contact
- [Tyler Whitmore](https://minderahealth.com/teams-tyler-whitmore/) - About Tyler Whitmore joined Mindera Health as a member of the Board of Directors in June 2024. Since January 2024, Mr. Whitmore has worked as Managing Director at Rippelos, an investment and management services firm. Prior to Rippelos, Mr. Whitmore served at Silicon Ranch, one of the nation’s largest utility-scale solar developers and owner/operators, as
- [Samuel “Bo” Bartholomew](https://minderahealth.com/samuel-bo-bartholomew/) - About Samuel “Bo” Bartholomew is CEO of EvidenceCare and Managing Partner of Rockmont Investments. Bo leads EvidenceCare’s effort to empower better care decisions within the EHR so that every clinical decision will provide the right care at the right time. He also serves on the board of ProviderTrust and Mindera Health with the goal of
- [Tobin](https://minderahealth.com/tobin-dickerson/) - About Tobin Dickerson joined MiNDERA from the The Scripps Research Institute where he was an Associate Professor in the Department of Chemistry and the Worm Institute for Research and Medicine from 2005-2019. He completed his BS with high honors in Chemistry from the University of Virginia in 1999, and subsequently was awarded his MA in Chemistry in
- [Terms of Use](https://minderahealth.com/terms-of-use/) - Mindera Health Terms of Service Welcome to the website operated by Mindera Health (“we”, “us” or “our”). The following terms and conditions (“Terms of Service” or “TOS”), govern your access to and use of our website, including any content, functionality and services offered on or through minderahealth.com (the “Site”). Please read these Terms of Service
- [Andrew Offer](https://minderahealth.com/team-mindera-health/mindera-health-team-andrew-offer/) - About Andrew Offer has been a member of the MiNDERA Board of Directors since 2015. He is a General Partner and the Chief Executive Officer of Scientific Health Development. With over 15 years of healthcare investment experience, Mr. Offer serves on the board of directors for most active SHD portfolio companies including Sight Sciences (Nasdaq:
- [Team-joseph-cook-iii](https://minderahealth.com/team-mindera-health/team-joseph-cook-iii/) - About Joseph Cook III has served as a member of our board of directors since August 2019. Since February 2003, Mr. Cook has served as a Managing Director at Mountain Group Partners, an investment firm with investments in the Life Sciences, AgTech and Technology sectors. From January 2001 until February 2003, Mr. Cook served as
- [Privacy Policy](https://minderahealth.com/privacy-policy/) - Introduction Mindera Health (“we”, “us” or “our”) respects your privacy and we are committed to protecting it through our compliance with this Privacy Policy. This Privacy Policy describes the types of information we may collect from you or that you may provide when you visit our Site or use our Services (as provided under our
- [In Office](https://minderahealth.com/in-office/) - Mind.Px In-Office Training Video
- [2023 In Office](https://minderahealth.com/2023-in-office/) - Psoriasis Predictive Test Training
- [Careers](https://minderahealth.com/careers/) - The company’s flagship test, Mind.Px™, provides a treatment algorithm to prospectively predict a patient’s response to expensive psoriasis biologic drugs. We’re currently introducing Mind.Px to the commercial market to materially improve the management of psoriasis while significantly reducing healthcare costs. Who We Are We are an experienced team of experts in dermatology research, precision medicine,
- [Psoriasis](https://minderahealth.com/psoriasis/) - Psoriasis: A Chronic Disease Psoriasis is a chronic autoimmune skin disorder that affects over 7.5 million patients in the United States and about 125 million people worldwide. It causes red, itchy scaly patches, most commonly on the knees, elbows, trunk and scalp. These lesions affect quality of life for many patients, and tends to go
- [Platform](https://minderahealth.com/platform/) - Mindera Health SkinAtlas™: The Dataset for Dermal Intelligence™ At Mindera Health, we are developing the SkinAtlas™, an expansive repository of skin data. This database is comprised of multiple data streams including molecular data from our dermal biomarker patch, as well as imaging data and patient metadata. The SkinAtlas™ contains samples both from various skin diseases,
- [2023 In Office Audio](https://minderahealth.com/2023-in-office-audio/) - Mindera Health In-Office Video Training
- [News](https://minderahealth.com/news/) - Stay up to date with how Mindera Health makes an impact in precision medicine.

## Landing Pages

- [Journal Club For Plaque Psoriasis](https://minderahealth.com/journal_club_for_plaque_psoriasis/) - For more information or additional assistance contact us and or: 858-810-6070 Mind.Px@minderahealth.com Mind.Px™ Journal Club Randomized, Prospective Study Validates The Clinical Utility of Mind.Px in Psoriasis Biologic Class Selections Enter your details below to register for our upcoming live webinar with our speaker Tobin Dickerson PhD, Chief Scientific Officer First Name Last Name Email Phone
- [Webinar Registration Navigating Biologic Class Selection In Plaque Psoriasis](https://minderahealth.com/webinar-registration-navigating-biologic-class-selection-in-plaque-psoriasis/) - Navigating Biologic Class Selection In Plaque Psoriasis Webinar Register To Attend Learn directly from our Chief Scientific Officer, Tobin Dickerson, PhD about biologic class selection in plaque psoriasis. Participate in a 30-minute peer session and explore the benefits of Mind.Px. Full Name Email Address Work Title Choose a Session Choose a session 5/1/25 @ 3:30pm

## Categories

- [Uncategorized](https://minderahealth.com/category/uncategorized/)
- [Leadership](https://minderahealth.com/category/leadership/)
- [Board](https://minderahealth.com/category/board/)
- [News](https://minderahealth.com/category/news/)
- [Scientific Advisors](https://minderahealth.com/category/scientific-advisors/)
- [Partnerships](https://minderahealth.com/category/partnerships/)

## Tags

- [plaque psoriasis](https://minderahealth.com/tag/plaque-psoriasis/)
- [General Services Administration (GSA)](https://minderahealth.com/tag/general-services-administration-gsa/)
- [Healthcare](https://minderahealth.com/tag/healthcare/)
- [Medi-cal](https://minderahealth.com/tag/medi-cal/)
- [National Psoriasis Foundation](https://minderahealth.com/tag/national-psoriasis-foundation/)
- [Mind.Px Test For Plaque Psoriasis](https://minderahealth.com/tag/mind-px-test-for-plaque-psoriasis/)
- [Test For Psoriasis](https://minderahealth.com/tag/test-for-psoriasis/)
- [NPF](https://minderahealth.com/tag/npf/)
- [Clinical Utility](https://minderahealth.com/tag/clinical-utility/)